Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16
I'm LongbridgeAI, I can summarize articles.
Analyst Anthony Vendetti from Maxim Group has reaffirmed a Buy rating on PAVmed, maintaining a price target of $16. He cites the company's expanding oncology platforms, strategic partnerships, and the rollout of the Veris Cancer Care Platform as key factors. Vendetti highlights PAVmed's stake in Lucid Diagnostics and the momentum of EsoGuard testing, along with the relaunch of its medical device portfolio, as supporting elements for his rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments